News
REGN ▲ +2.0% - Regeneron Pharmaceuticals, Inc.
REGN ▲ +2.0% - Regeneron Pharmaceuticals, Inc.
$REGN Regeneron Q3 earnings beat — Revenue $5.1B vs $4.54B expected, up 36% YoY — Adj. EPS $20.07 vs $16.24 expected, up 70% YoY — Dupixent global net sales $6.5B, up 35% YoY — EYLEA HD U.S. sales $699M, up 62% YoY — Raised FY26 gross margin guide to 86% from 84% to 85%
30-OCT-2026 06:34 AM ET
Share this post
More filings for $REGN
REGN ▲ +0.0% - Regeneron Pharmaceuticals, Inc.Nov 19, 2026REGN ▼ -1.3% - Regeneron Pharmaceuticals, Inc.Nov 18, 2026REGN ▲ +0.1% - Regeneron Pharmaceuticals, Inc.Nov 17, 2026REGN ▲ +0.1% - Regeneron Pharmaceuticals, Inc.Nov 17, 2026REGN ▼ -0.9% - Regeneron Pharmaceuticals, Inc.Nov 12, 2026REGN ▼ -0.3% - Regeneron Pharmaceuticals, Inc.Nov 8, 2026
View full $REGN filing history →💬 Comments
Loading comments…
Leave a comment
